4.7 Article

A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer

Related references

Note: Only part of the references are listed.
Article Multidisciplinary Sciences

The landscape of somatic copy-number alteration across human cancers

Rameen Beroukhim et al.

NATURE (2010)

Article Medicine, Research & Experimental

Unique Biology of Mcl-1: Therapeutic Opportunities in Cancer

Gordon Shore et al.

CURRENT MOLECULAR MEDICINE (2008)

Article Neurosciences

Bcl-xL inhibitor ABT-737 reveals a dual role for Bcl-xL in synaptic transmission

John A. Hickman et al.

JOURNAL OF NEUROPHYSIOLOGY (2008)

Article Multidisciplinary Sciences

Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis

Mai Nguyen et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)

Article Medicine, General & Internal

Prophylactic cranial irradiation in extensive small-cell lung cancer

Ben Slotman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

Article Oncology

Management of small-cell lung cancer

N Thatcher et al.

ANNALS OF ONCOLOGY (2005)

Review Medicine, General & Internal

Drug therapy: Multidisciplinary management of lung cancer

A Spira et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)

Article Oncology

New guidelines to evaluate the response to treatment in solid tumors

F Duffaud et al.

BULLETIN DU CANCER (2000)

Article Oncology

New guidelines to evaluate the response to treatment in solid Tumors

P Therasse et al.

JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)